Determination of the eicosanoid response to inflammatory stimuli in whole blood and its pharmacological modulation ex vivo

Journal of Immunological Methods

Volumn 277, Issue 1-2, 2003, Pages 53-63

  Von Aulock, Sonja ^a   Hermann, Corinna ^a   Hartung, Thomas ^a  

^a UNIVERSITY OF KONSTANZ   (Germany)

Author keywords

Eicosanoids; Human; Lipopolysaccharide; Whole blood

Indexed keywords

4 AMINOBENZOIC ACID; ACETYLSALICYLIC ACID; ARACHIDONIC ACID; CELECOXIB; CYCLOOXYGENASE 2; DICLOFENAC; FLURBIPROFEN; IBUPROFEN; IBUPROFEN KLINGE; ICOSANOID; INDOMETACIN; LEUKOTRIENE B4; LIPOPOLYSACCHARIDE; PARACETAMOL; PHENYLBUTAZONE; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE INHIBITOR; ROFECOXIB; THROMBOXANE B2;

ACUTE PHASE RESPONSE; ARTICLE; BLOOD; CONTROLLED STUDY; CYTOKINE RELEASE; HUMAN; HUMAN EXPERIMENT; INFLAMMATION; KINETICS; NORMAL HUMAN; PHARMACOLOGICAL STIMULATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STIMULUS; STIMULUS RESPONSE; SUPERNATANT;

EID: 0038546897     PISSN: 00221759     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-1759(03)00180-7     Document Type: Article

References (43)

1. 2 production in human monocytes. Crit. Care Med. 25:1997;430-434.
2. 2 production of polymorphonuclear leukocytes via tumor necrosis factor alpha. Biochem. Biophys. Res. Commun. 168:1990;857-862.
3. Beck J., Rondot P., Catinot L., Falcoff E., Kirchner H., Wietzerbin J. Increased production of interferon gamma and tumor necrosis factor precedes clinical manifestation in multiple sclerosis: do cytokines trigger off exacerbations? Acta Neurol. Scand. 78:1988;318-323.
4. Blain H., Boileau C., Lapicque F., Nedelec E., Loeuille D., Guillaume C., Gaucher A., Jeandel C., Netter P., Jouzeau J.Y. Limitation of the in vitro whole blood assay for predicting the COX selectivity of NSAIDs in clinical use. Br. J. Clin. Pharmacol. 53:2002;255-265.
5. Brideau C., Kargman S., Liu S., Dallob A.L., Ehrich E.W., Rodger I.W., Chan C.C. A human whole blood assay for clinical evaluation of biochemical efficacy of cyclooxygenase inhibitors. Inflamm. Res. 45:1996;68-74.
6. Brideau C., Van Staden C., Chan C.C. In vitro effects of cyclooxygenase inhibitors in whole blood of horses, dogs, and cats. Am. J. Vet. Res. 62:2001;1755-1760.
7. Chernoff A.E., Granowitz E.V., Shapiro L., Vannier E., Lonnemann G., Angel J.B., Kennedy J.S., Rabson A.R., Wolff S.M., Dinarello C.A. A randomized, controlled trial of IL-10 in humans. Inhibition of inflammatory cytokine production and immune responses. J. Immunol. 154:1995;5492-5499.
8. de Leval X., Delarge J., Devel P., Neven P., Michaux C., Masereel B., Pirotte B., David J.L., Henrotin Y., Dogn J.M. Evaluation of classical NSAIDs and COX-2 selective inhibitors on purified ovine enzymes and human whole blood. Prostaglandins Leukot. Essent. Fat. Acids. 64:2001;211-216.
9. Dessein A.J., Lee T.H., Elsas P., Ravalese J.d., Silberstein D., David J.R., Austen K.F., Lewis R.A. Enhancement by monokines of leukotriene generation by human eosinophils and neutrophils stimulated with calcium ionophore A23187. J. Immunol. 136:1986;3829-3838.
10. Diterich I., Harter L., Hassler D., Wendel A., Hartung T. Modulation of cytokine release in ex vivo-stimulated blood from borreliosis patients. Infect. Immun. 69:2001;687-694.
11. 4. J. Clin. Invest. 83:1989;970-977.
12. Elsasser-Beile U., von Kleist S., Fischer R., Martin M., Wetterauer U., Gallati H., Monting J.S. Impaired cytokine production in whole blood cell cultures of patients with urological carcinomas. J. Cancer Res. Clin. Oncol. 119:1993;430-433.
13. Ertel W., Krombach F., Kremer J.P., Jarrar D., Thiele V., Eymann J., Muenzing S., Faist E., Messmer K., Schildberg F.W. Mechanisms of cytokine cascade activation in patients with sepsis: normal cytokine transcription despite reduced CD14 receptor expression. Surgery. 114:1993;243-250. (Discussion 250-1).
14. Fradin A., Zirrolli J.A., Maclouf J., Vausbinder L., Henson P.M., Murphy R.C. Platelet-activating factor and leukotriene biosynthesis in whole blood. A model for the study of transcellular arachidonate metabolism. J. Immunol. 143:1989;3680-3685.
15. Frankenburg S., Klaus S. Production of interferon gamma in cultures of whole blood obtained in the course of and after healing of cutaneous leishmaniasis. Ann. Trop. Med. Parasitol. 85:1991;401-405.
16. Glaser K., Sung M.L., O'Neill K., Belfast M., Hartman D., Carlson R., Kreft A., Kubrak D., Hsiao C.L., Weichman B. Etodolac selectively inhibits human prostaglandin G/H synthase 2 (PGHS-2) versus human PGHS-1. Eur. J. Pharmacol. 281:1995;107-111.
17. 2 and thromboplastin activity in whole blood of males, females and females on oral contraceptives. Thromb. Haemost. 61:1989;493-496.
18. Hartung T., Docke W.D., Gantner F., Krieger G., Sauer A., Stevens P., Volk H.D., Wendel A. Effect of granulocyte colony-stimulating factor treatment on ex vivo blood cytokine response in human volunteers. Blood. 85:1995;2482-2489.
19. Hartung T., Pitrak D.L., Foote M., Shatzen E.M., Verral S.C., Wendel A. Filgrastim restores interleukin-2 production in blood from patients with advanced human immunodeficiency virus infection. J. Infect. Dis. 178:1998;686-692.
20. Hartung T., Doecke W.D., Bundschuh D., Foote M.A., Gantner F., Hermann C., Lenz A., Milwee S., Rich B., Simon B., Volk H.D., von Aulock S., Wendel A. Effect of filgrastim treatment on inflammatory cytokines and lymphocyte functions. Clin. Pharmacol. Ther. 66:1999;415-424.
21. Hartung T., von Aulock S., Freitag M., Hoxtermann S., Stucker M., Hoffmann K., Altmeyer P., Kottke A., Wendel A. Blood cytokine response of low-dose molgramostim (rhGM-CSF)-treated patients. Cytokine. 12:2000;1570-1574.
22. Hinz B., Brune K. Specific COX-2 inhibitors: prospects of therapy with new analgesic and anti-inflammatory substances. Wien. Klin. Wochenschr. 111:1999;103-112.
23. Iniguez M.A., Pablos J.L., Carreira P.E., Cabre F., Gomez-Reino J.J. Detection of COX-1 and COX-2 isoforms in synovial fluid cells from inflammatory joint diseases. Br. J. Rheumatol. 37:1998;773-778.
24. Juergens U.R., Christiansen S.C., Stevenson D.D., Zuraw B.L. Arachidonic acid metabolism in monocytes of aspirin-sensitive asthmatic patients before and after oral aspirin challenge. J. Allergy Clin. Immunol. 90:1992;636-645.
25. Langezaal I., Coecke S., Hartung T. Whole blood cytokine response as a measure of immunotoxicity. Toxicol. In Vitro. 15:2001;313-318.
26. Mancini J.A., Vickers P.J., O'Neill G.P., Boily C., Falgueyret J.P., Riendeau D. Altered sensitivity of aspirin-acetylated prostaglandin G/H synthase-2 to inhibition by nonsteroidal anti-inflammatory drugs. Mol. Pharmacol. 51:1997;52-60.
27. Mitchell J.A., Akarasereenont P., Thiemermann C., Flower R.J., Vane J.R. Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc. Natl. Acad. Sci. U. S. A. 90:1993;11693-11697.
28. 2 release from human monocytes treated with C3b or bacterial lipopolysaccharide. Biochim. Biophys. Acta. 927:1987;149-157.
29. Nusing R., Lesch R., Ullrich V. Immunohistochemical localization of thromboxane synthase in human tissues. Eicosanoids. 3:1990;53-58.
30. Patrignani P., Panara M.R., Greco A., Fusco O., Natoli C., Iacobelli S., Cipollone F., Ganci A., Creminon C., Maclouf J.et al. Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases. J. Pharmacol. Exp. Ther. 271:1994;1705-1712.
31. 2 release in polymorphonuclear leukocytes, macrophages and platelets: effect of IL-1 receptor antagonist. Mol. Cell. Biochem. 159:1996;163-168.
32. Reinke P., Docke W.D., Kox W., Zuckermann H., Volk H.D. New developments in the immunodiagnosis of patients in intensive care. Dtsch. Med. Wochenschr. 124:1999;1527-1529.
33. Revhaug A., Michie H.R., Manson J.M., Watters J.M., Dinarello C.A., Wolff S.M., Wilmore D.W. Inhibition of cyclo-oxygenase attenuates the metabolic response to endotoxin in humans. Arch. Surg. 123:1988;162-170.
34. Riendeau D., Percival M.D., Brideau C., Charleson S., Dube D., Ethier D., Falgueyret J.P., Friesen R.W., Gordon R., Greig G., Guay J., Mancini J., Ouellet M., Wong E., Xu L., Boyce S., Visco D., Girard Y., Prasit P., Zamboni R., Rodger I.W., Gresser M., Ford-Hutchinson A.W., Young R.N., Chan C.C. Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2. J. Pharmacol. Exp. Ther. 296:2001;558-566.
35. Rola-Pleszczynski M. Leukotrienes and the immune system. J. Lipid Mediat. 1:1989;149-159.
36. 4 and PAF. Med. Inflamm. 1:1992;5-8.
37. Rome L.H., Lands W.E. Structural requirements for time-dependent inhibition of prostaglandin biosynthesis by anti-inflammatory drugs. Proc. Natl. Acad. Sci. U. S. A. 72:1975;4863-4865.
38. Roth G.J., Stanford N., Majerus P.W. Acetylation of prostaglandin synthase by aspirin. Proc. Natl. Acad. Sci. U. S. A. 72:1975;3073-3076.
39. Saareks V., Riutta A., Mucha I., Alanko J., Vapaatalo H. Nicotine and cotinine modulate eicosanoid production in human leukocytes and platelet rich plasma. Eur. J. Pharmacol. 248:1993;345-349.
40. Sauer A., Hartung T. LTD4 augments TNF release in vivo and in vitro. Agents Actions. 41:1994;C155-C156.
41. von Aulock S., Boneberg E.M., Hartung T. Intermittent G-CSF (filgrastim) treatment cannot induce lymphocytosis in volunteers. Clin. Pharmacol. Ther. 68:2000;104.
42. Zangerle P.F., De Groote D., Lopez M., Meuleman R.J., Vrindts Y., Fauchet F., Dehart I., Jadoul M., Radoux D., Franchimont P. Direct stimulation of cytokines (IL-1 beta, TNF-alpha, IL-6, IL-2, IFN-gamma and GM-CSF) in whole blood: II. Application to rheumatoid arthritis and osteoarthritis. Cytokine. 4:1992;568-575.
43. Zheng H., Crowley J.J., Chan J.C., Hoffmann H., Hatherill J.R., Ishizaka A., Raffin T.A. Attenuation of tumor necrosis factor-induced endothelial cell cytotoxicity and neutrophil chemiluminescence. Am. Rev. Respir. Dis. 142:1990;1073-1078.